Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1177/1362361320972277 | ||||
| Año | 2021 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Diagnosis of Autism Spectrum Conditions (ASC) can be an extended procedure since ASC tend to both vary greatly across individual symptoms and diagnostic pathways with serious challenges to opportune access and diagnosis in low resource settings. We adapted the Q-CHAT-25 for use in a routine health check-ups programme at Chilean primary health clinics by developing a 10-item version of this questionnaire recruiting n = 287 (F: 112/M: 175) participants (Controls: n = 125, F: 58/M: 67; Developmental Delay: n = 149, F: 53/M: 96; Autism Spectrum Conditions: n = 13, F: 1/M: 12). Our findings show that the Q-CHAT-10 can be successfully applied in health-check programmes. The results for the Q-CHAT-10 show high internal consistency (Cronbach’s α: 0.85) and good overall performance, significantly correlating (r = 0.79, p < 0.0001) with the Q-CHAT-25. The Q-CHAT-10 had a sensitivity of 92.86% and a specificity of 76.86% in the Developmental Delay sample. The positive predictive value was 48% with a positive likelihood ratio of 4.01 and a negative likelihood ratio of 0.09 with a post-test probability of disease of 19%. This study provides evidence that the implementation of Autism Spectrum Condition screening programmes using the Q-CHAT-10 is a cost-effective measure that improves diagnosis of Autism Spectrum Conditions in those participating in conditional cash transfer programmes in low- and middle-income countries or low resource setting in high income countries. Lay abstract: Getting a diagnosis of autism can take long, because autism is different across people, but also because it depends on the way it gets diagnosed. This is especially important in poorer countries or in the case of poor people living in wealthier countries that have significant groups of disadvantaged communities. We adapted a 10-item version of the Q-CHAT-25 questionnaire for use in routine health check-ups programme in Chile and recruited 287 participants under the age of three divided into three groups: Controls (125), Developmental Delay (149) and Autism Spectrum Condition (13). Our results show that a short questionnaire for autism screening can be successfully applied in a health-check programme in poor resource settings. Our results show that our questionnaire had good overall performance, not different to its longer version, the Q-CHAT-25. Our questionnaire was autism specific, with good sensitivity and reliability, and is suitable to be used in a screening setting. This study provides evidence that the implementation of Autism Spectrum Condition screening programmes using the Q-CHAT-10 provides value for money and improves diagnosis of Autism Spectrum Condition in those participating in routine health check-up programmes in developing countries or poor areas of wealthy countries.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Roman-Urrestarazu, Andres | Hombre |
Autism Research Centre - Reino Unido
Cambridge Institute of Public Health - Reino Unido UNIV CAMBRIDGE - Reino Unido |
| 2 | Yáñez, Carolina | Mujer |
Universidad de Chile - Chile
|
| 3 | Lopez-Gari, Claudia | Mujer |
Universidad de Chile - Chile
|
| 4 | Elgueta, Constanza | Mujer |
Universidad de Chile - Chile
|
| 5 | Allison, Carrie | Mujer |
Autism Research Centre - Reino Unido
UNIV CAMBRIDGE - Reino Unido |
| 6 | Brayne, Carol | Mujer |
Cambridge Institute of Public Health - Reino Unido
UNIV CAMBRIDGE - Reino Unido |
| 7 | TRONCOSO-SCHIFFERLI, LUCY MONICA | Mujer |
Universidad de Chile - Chile
|
| 8 | Baron-Cohen, Simon | Hombre |
Autism Research Centre - Reino Unido
UNIV CAMBRIDGE - Reino Unido |
| Fuente |
|---|
| European Union |
| Medical Research Council |
| Wellcome Trust |
| Horizon 2020 |
| Horizon 2020 Framework Programme |
| National Institute for Health Research |
| European Federation of Pharmaceutical Industries and Associations |
| MRC |
| Innovative Medicines Initiative |
| EFPIA |
| Simons Foundation Autism Research Initiative |
| AUTISM |
| Autism Research Trust |
| NIHR Cambridge Biomedical Research Centre |
| National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust |
| Autistica |
| SFARI |
| Innovative Medicines Initiative 2 Joint Undertaking (JU) |
| Gillings Fellowship in Global Public Health and Autism Research |
| AUTISM SPEAKS |
| Agradecimiento |
|---|
| The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: A.R-U. received funding from the Gillings Fellowship in Global Public Health and Autism Research, Grant Award YOG054 to the Cambridge Institute of Public Health (PI Carol Brayne). S.B-C. received funding from Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 777394. The JU receives support from the European Union?s Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. S.B-C. also received funding from the Autism Research Trust, Autistica, the MRC, the Wellcome Trust and the NIHR Cambridge Biomedical Research Centre. The research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust. |
| The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: A.R-U. received funding from the Gillings Fellowship in Global Public Health and Autism Research, Grant Award YOG054 to the Cambridge Institute of Public Health (PI Carol Brayne). S.BC. received funding from Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 777394. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. S.B-C. also received funding from the Autism Research Trust, Autistica, the MRC, the Wellcome Trust and the NIHR Cambridge Biomedical Research Centre. The research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust. |